TRODELVY PROVIDED IMPRESSIVE RESPONSES
Overall response rate*
- 34.3% ORR based on BICR (95% CI: 25.4; 44.0)1†
Duration of response
- 9.1 months DOR based on BICR (95% CI: 4.6; 11.3)1†
Blinded, independent, central review (BICR) of staging scans was obtained for the 56 patients determined to have a CR, PR, or ≥20% reduction in target lesions by investigator assessment. Since the BICR analyses were conducted in a subgroup of preselected patients based on investigator assessment, the results are subject to bias and should be interpreted with caution.
Tumor imaging occurred every 8 weeks initially with confirmatory scans to confirm responses 4 to 6 weeks after the first apparent response.
CI=confidence interval; CR=complete response; DOR=duration of response; ORR=overall response rate; PR=partial response.